⚠ Focus Is Also ConcentrationModerate threat

Eli Lilly (LLY) — threat to the moat

Betting deep on a few fields magnifies every setback in them.

Therapeutic focus compounds expertise, but it also concentrates risk, and Lilly's heavy bet on metabolic disease means its fortunes ride disproportionately on a few areas of science going well. The same focus that produced the incretin triumph would magnify the damage from a setback in that field — a safety problem across the drug class, a scientific dead end in the next generation, a competitor's breakthrough — because Lilly has less diversification to cushion it than a company spread across all of medicine. Concentration cuts both ways.

Oncology and immunology share of revenue (%)23.7%H1 202517.4%H1 2026(Oncology + immunology) / revenue; Lilly Form 10-Q, June 2026
The other two areas are growing, but shrinking as a share of the company.

The danger is that Lilly could be caught over-committed to areas that disappoint or get disrupted. Betting deeply on a few fields means that if one stalls — if metabolic science yields diminishing returns, or a rival redefines the field — Lilly has fewer other engines to fall back on. And the areas it has chosen not to pursue are opportunities forgone; a focused company that misses a revolution outside its concentration cannot easily pivot to catch up.

Lilly's focus has been vindicated spectacularly by the incretin franchise, and its chosen areas — metabolism, oncology, immunology, neuroscience — are among the largest and most important in medicine, offering deep runways. But an owner should recognize that focus is concentration by another name, that it ties Lilly's future unusually tightly to the continued fertility of a few fields, and that the strategy which produced today's triumph — a tirzepatide franchise at $49.5 billion over the twelve months to June 202612 — would, in a different scenario, concentrate the pain of a stumble.

References
  1. ReportedBut an owner should recognize that focus is concentration by another name, that it ties Lilly's future unusually tightly to the continued fertility of a few fields, and that the strategy which produced today's triumph — a tirzepatide franchise at $49.5 billion over the twelve months to June 2026 — would, in a different scenario, concentrate the pain of a stumble.
    Eli Lilly Form 10-Q, quarter ended 30 June 2026 - revenue $22,974M (+48%): Mounjaro $9,943M (U.S. $4,791M, outside $5,152M), Zepbound $4,928M, Jardiance $1,232M, Trulicity $1,219M, Verzenio $1,474M; oncology $2,570M, immunology $1,417M, neuroscience $429M; volume +60% and price -13% (U.S. +37%/-3%, outside +113%/-36%); gross margin 85.8% (84.3%); R&D $3,819M; MS&A $3,430M; acquired IPR&D $2,776M; special charges $703M; tax rate 23.3% (16.5%); net income $7,095M; diluted EPS $7.94; H1 capital expenditure $5,259M and operating cash flow $16,023M — Q2 2026 · publ. August 2026 · source ↗
  2. Moat Explorer calcBut an owner should recognize that focus is concentration by another name, that it ties Lilly's future unusually tightly to the continued fertility of a few fields, and that the strategy which produced today's triumph — a tirzepatide franchise at $49.5 billion over the twelve months to June 2026 — would, in a different scenario, concentrate the pain of a stumble.
    Moat Explorer calculation from Lilly's Forms 10-K FY2021-FY2025 and the Q2 2026 10-Q: tirzepatide (Mounjaro + Zepbound) $36,507M in 2025, $14,871M in Q2 2026 ($8,580M), trailing twelve months $49,466M; trailing revenue $79,666M; margins and shares as stated — 2021 to Q2 2026 · publ. 2026-09-23 · source ↗
Sources
Generated September 23, 2026